4 Midcap UTI Mutual Fund Stocks to Watch for Future Multibagger Potential: Dixon, Ajanta Pharma, Astral and Dr Lal PathLabs

UTI mutual fund stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Dixon, Ajanta Pharma, Astral and Dr Lal PathLabs meet that test, with market caps from Rs 32,757 crore to Rs 77,049 crore and Dixon offering the highest return on equity at 30.76%. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and UTI Mutual Fund or one of its schemes listed among its top domestic institutional holders, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.

This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and UTI Mutual Fund or one of its schemes listed among its top domestic institutional holders, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening UTI mutual fund stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 28 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are UTI Mutual Fund Stocks and Why Do They Attract Multibagger Interest?

UTI mutual fund stocks are shares of mid sized companies in which UTI Mutual Fund or one of its schemes is named among the top domestic institutional holders in the latest shareholding pattern. The four here cover electronics manufacturing, pharmaceuticals, pipes and diagnostics.

When a respected fund house like UTI Mutual Fund holds a large stake, it shows that its research teams have studied the business closely and backed it with investors money. For UTI mutual fund stocks, both FY26 and the latest quarter showed growth. A sensible way to study UTI mutual fund stocks is to look at profit growth, returns and valuation side by side. Below, each of UTI mutual fund stocks gets its own breakdown of growth, returns and valuation. Treat UTI mutual fund stocks as a research list, since share prices and rankings change with every earnings season.

UTI Mutual Fund Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 28 October 2026. Dixon combines the lowest PE of the group, 37.01, with the highest return on equity, 30.76%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Dixon Technologies	11,400	77,049	37.01	45.19	30.76%	0.21	9,600.00 to 17,299.00
Ajanta Pharma	3,459.80	43,550	38.37	36.35	23.33%	0.06	2,380.20 to 3,796.00
Astral	1,360.60	36,939	64.16	36.61	13.18%	0.06	1,311.60 to 1,768.70
Dr Lal PathLabs	1,922.30	32,757	59.96	60.75	20.13%	0.08	1,272.60 to 2,038.60

Dixon: 71.44% Profit CAGR Since FY22

Dixon Technologies is an electronics manufacturing services company that makes televisions, phones, appliances and lighting for brands. It reported FY26 revenue of Rs 49,585.84 crore, up 27.53% year on year, and net profit of Rs 1,644.25 crore, up 33.40%. Net profit has compounded at 71.44% a year since FY22, while revenue has grown 46.72% a year. Operating margin was 3.95% in FY26. The debt-to-equity ratio is 0.21.

In the June 2026 quarter, revenue rose 25.23% to Rs 16,075.95 crore and net profit grew 156.35% to Rs 717.83 crore. The share price has gained 114.81% over five years. The stock trades at a PE of 37.01 against an industry PE of 45.19, below the sector average, with a return on equity of 30.76%.

Ajanta Pharma: Return on Equity of 23.33%

Ajanta Pharma sells branded generics in ophthalmology, dermatology, cardiology and pain management in India, Africa and Asia. It reported FY26 revenue of Rs 5,624.93 crore, up 18.60% year on year, and net profit of Rs 1,056 crore, up 14.73%. Net profit has compounded at 10.33% a year since FY22, while revenue has grown 12.94% a year. Operating margin was 28.74% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

The stock trades at a PE of 38.37 against an industry PE of 36.35, with a return on equity of 23.33%. In the June 2026 quarter, revenue rose 27.68% to Rs 1,696.86 crore and net profit grew 30.89% to Rs 334.22 crore. The share price has gained 125.31% over five years and 35.42% over the past year. Domestic institutions raised their holding from 17.90% in September 2025 to 21.94% in September 2026.

Astral: Debt-to-Equity of 0.06

Astral makes CPVC and PVC pipes, fittings, adhesives and water tanks for plumbing and drainage in homes and buildings. It reported FY26 revenue of Rs 6,615.90 crore, up 12.64% year on year, and net profit of Rs 534.70 crore, up 3.04%. Revenue has compounded at 10.55% a year since FY22. Operating margin was 16.54% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

In the June 2026 quarter, revenue rose 16.09% to Rs 1,590.80 crore and net profit grew 51.77% to Rs 120.20 crore. Domestic institutions raised their holding from 14.90% in June 2025 to 21.31% in June 2026. The stock trades at a PE of 64.16 against an industry PE of 36.61, with a return on equity of 13.18%.

Dr Lal PathLabs: Return on Equity of 20.13%

Dr Lal PathLabs is one of India's leading diagnostic chains, running laboratories and collection centres across the country. It reported FY26 revenue of Rs 2,864.18 crore, up 12.11% year on year, and net profit of Rs 509.75 crore, up 3.56%. Net profit has compounded at 9.83% a year since FY22, while revenue has grown 7.56% a year. Operating margin was 30.90% in FY26. The debt-to-equity ratio is 0.08, which keeps interest costs low.

The stock trades at a PE of 59.96 against an industry PE of 60.75, below the sector average, with a return on equity of 20.13%. In the June 2026 quarter, revenue rose 18.87% to Rs 829.60 crore and net profit grew 27.24% to Rs 170.50 crore. The share price is up 19.11% over the past year. Domestic institutions raised their holding from 17.91% in June 2025 to 21.59% in June 2026.

UTI Mutual Fund Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these UTI mutual fund stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	4-Year Net Profit CAGR	Operating Margin (Latest Quarter)
Dixon	49,585.84	1,644.25	27.53%	46.72%	71.44%	6.43%
Ajanta Pharma	5,624.93	1,056	18.60%	12.94%	10.33%	30.41%
Astral	6,615.90	534.70	12.64%	10.55%	2.19%	15.46%
Dr Lal PathLabs	2,864.18	509.75	12.11%	7.56%	9.83%	35.03%

Check the Univest Screener for live data on these UTI mutual fund stocks

Institutional Holding in Dixon, Ajanta Pharma, Astral and Dr Lal PathLabs

Institutional holding shows who is backing these UTI mutual fund stocks alongside the promoter. The table uses the latest reported quarter for each. Dixon has the deepest institutional backing, with FII and DII together holding 47.67% as of September 2026. Domestic institutions increased their holding over the past year in Ajanta Pharma (from 17.90% to 21.94%), Astral (from 14.90% to 21.31%) and Dr Lal PathLabs (from 17.91% to 21.59%).

Stock	Promoter	FII	DII	Public	Quarter
Dixon	28.50%	18.96%	28.71%	23.83%	September 2026
Ajanta Pharma	63.47%	7.63%	21.94%	6.96%	September 2026
Astral	54.22%	13.89%	21.31%	10.58%	June 2026
Dr Lal PathLabs	53.19%	17.36%	21.59%	7.86%	June 2026

Risks to Weigh in UTI Mutual Fund Stocks

Being careful with UTI mutual fund stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: Astral trades at a PE of 64.16 against an industry PE of 36.61, so earnings need to keep growing to support the price.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between UTI Mutual Fund Stocks

Picking from UTI mutual fund stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (36.35 to 60.75) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Dixon, Ajanta Pharma, Astral and Dr Lal PathLabs live prices.

Conclusion

Among UTI mutual fund stocks, Dixon stands out for the highest return on equity at 30.76%, Ajanta Pharma for the biggest five-year price gain at 125.31%, Astral for a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06 and Dr Lal PathLabs for a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.08. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing UTI mutual fund stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on UTI Mutual Fund Stocks to Watch

Which are the best UTI mutual fund stocks to watch for multibagger potential?

Ans. Dixon, Ajanta Pharma, Astral and Dr Lal PathLabs are the 4 names this list highlights, with market caps of Rs 77,049 crore, Rs 43,550 crore, Rs 36,939 crore and Rs 32,757 crore respectively. Dixon is notable for the highest return on equity at 30.76%. Ajanta Pharma stands out for the biggest five-year price gain at 125.31%. Astral offers a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06. Dr Lal PathLabs brings a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.08. These are watchlist names for UTI mutual fund stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Dixon a good stock for long-term investors?

Ans. Dixon has a return on equity of 30.76%, a PE of 37.01 against an industry PE of 45.19 and a market cap of Rs 77,049 crore. Net profit has compounded at 71.44% a year since FY22, and FY26 revenue rose 27.53% while June 2026 quarter net profit grew 156.35%. Long-term returns in UTI mutual fund stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Ajanta Pharma become a multibagger from here?

Ans. Ajanta Pharma has already gained 125.31% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in UTI mutual fund stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 10.33% a year since FY22, and FY26 revenue rose 18.60%. At a PE of 38.37 against an industry PE of 36.35, valuation should be checked against that growth before investing.

What is the market cap of Dixon, Ajanta Pharma, Astral and Dr Lal PathLabs?

Ans. As of 28 October 2026, Dixon has a market cap of Rs 77,049 crore, Ajanta Pharma has a market cap of Rs 43,550 crore, Astral has a market cap of Rs 36,939 crore and Dr Lal PathLabs has a market cap of Rs 32,757 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on UTI mutual fund stocks.

What are the risks of investing in UTI mutual fund stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Astral trades at a PE of 64.16 against an industry PE of 36.61, so earnings growth needs to hold up.

Why is Astral trading at a PE of 64.16?

Ans. Astral's PE of 64.16 compares with an industry PE of 36.61. The market is paying a premium for latest-quarter profit growth of 51.77%, which also means the stock is more sensitive if growth slows. Investors in UTI mutual fund stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Dixon, Ajanta Pharma, Astral and Dr Lal PathLabs?

Ans. As of the latest reported quarter, FII and DII together hold 47.67% of Dixon (18.96% and 28.71%), 29.57% of Ajanta Pharma (7.63% and 21.94%), 35.20% of Astral (13.89% and 21.31%) and 38.95% of Dr Lal PathLabs (17.36% and 21.59%). Rising institutional holding is a useful signal in UTI mutual fund stocks, though it should be read with earnings trends rather than on its own.